CCL20

Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results

Retrieved on: 
수요일, 9월 13, 2023
China Biologic Products, IBN, Injection, Plaque, Asthma, NVS, Therapy, Dermis, AMD, University Medical Center, Hook effect, I&I, 3D, European Medicines Agency, COVID-19, Clinical trial, Infection, Inflammation, IL-17A, Psoriasis, EMA, VHH, LLY, UCB, Novartis, Patient, Lilly, Risk, Max Planck Institute for Multidisciplinary Sciences, Brussels Stock Exchange, UMG, Mab, CCL20, CXCL1, AF, Research, Moonlake, NYSE, Max Planck Society, Skin, Autoimmunity, Disease, Pharmaceutical industry, Vaccine

JERUSALEM, Sept. 13, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announces encouraging results in a preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.

Key Points: 
  • Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-vivo animal study results anticipated in early 2024
    JERUSALEM, Sept. 13, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announces encouraging results in a preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.
  • These results suggest NanoAbs’ therapeutic potential to relieve symptoms of plaque psoriasis.
  • Research shows that targeting IL-17F isoform in addition to IL-17A provides higher efficacy in treating plaque psoriasis.
  • Scinai recently started to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for plaque psoriasis to evaluate the effective dose and schedule of treatment, with in-vivo animal studies anticipated in early 2024.

Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Retrieved on: 
목요일, 5월 25, 2023
Human, CD47, PD, AE, CCL2, Bachelor of Medicine, Bachelor of Surgery, Aes, Clinical trial, RECIST, Cancer, Mirvetuximab soravtansine, PROC, ASCO, Monocyte, Patient, Autoimmune disease, CCL20, CCL22, CD4, IRR, Safety, Generic drug, Pharmaceutical industry, Palladium, Vaccine, CD40

AUSTIN, TX and DURHAM, NC, May 25, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of complete dose-escalation data from the Phase 1A monotherapy clinical trial of SL-172154 in PROC. These data will be featured in a poster presentation at the ASCO Annual Meeting, being held both virtually and in Chicago, IL from June 2-6, 2023.

Key Points: 
  • These data will be featured in a poster presentation at the ASCO Annual Meeting, being held both virtually and in Chicago, IL from June 2-6, 2023.
  • Our ongoing clinical trial of SL-172154 in combination with liposomal doxorubicin remains on track, and we expect to share initial data midyear.
  • Session Date and Time: Monday, June 5 at 1:15 p.m. CT
    SL-172154 was generally well tolerated in heavily pretreated PROC patients.
  • Maximal CD47 and CD40 target engagement and CD40-dependent PD effects were observed with ≥ 3 mg/kg of SL-172154.